1 cognitive-behavioral/pharmacologic group (CB-PHARM), 2) attention-control/pharmacologic group, or 3)

2 ; pediatrics; children; pain assessment; non-pharm*; analges*.

3 Sci 1220:49-59, 2011; Hashimoto et al., Curr Pharm Des 17:985-989, 2011).

4  receiving either C-ECT (10 treatments) or C-Pharm for 6 months.

5 ks compared with 6.7 +/- 4.6 weeks for the C-Pharm group (P = .13).

6 er state and trait anxiety scores for the CB-PHARM group at the 15-month followup.

7                                     In the C-Pharm group, 31.6% experienced disease relapse, 46.3% co

8 depression, compared between the C-ECT and C-Pharm groups.

9 rted as cost-effective in a previous review (Pharm Pract (Granada), 2014;12:493), but methods used to

10 active site of Chk-1 kinase, using the FlexX-Pharm program.

11                                          The Pharm-TCR intervention was effective in reducing the nee

12                                          M/W Pharm was used for PK modeling.

13                             Both C-ECT and C-Pharm were shown to be superior to a historical placebo